Full text biomedical articles

Meal Effects Confound Attempts to Counteract Rabeprazole-Induced Hypochlorhydria Decreases in Atazanavir Absorption

Kathleen Panter Faber, Hsin-Fang Wu, Marc R. Yago, Xiaohui Xu, Pathanjali Kadiyala, Lynda A. Frassetto, Leslie Z. Benet
Pharm Res. Author manuscript; available in PMC 2020 Apr 23.
Published in final edited form as: Pharm Res. 2017 Mar; 34(3): 619–628. Published online 2016 Dec 27. doi: 10.1007/s11095-016-2090-2


Article   |   PubReader   |   PDF–711K   |   Cite

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Charles S. Venuto, Katie Mollan, Qing Ma, Eric S. Daar, Paul E. Sax, Margaret Fischl, Ann C. Collier, Kimberly Y. Smith, Camlin Tierney, Gene D. Morse
J Antimicrob Chemother. 2014 Dec; 69(12): 3300–3310. Published online 2014 Aug 25. doi: 10.1093/jac/dku303


Article   |   PubReader   |   PDF–501K   |   Cite

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)

Jose R. Castillo-Mancilla, Christina L. Aquilante, Michael F. Wempe, Laura M. Smeaton, Cynthia Firnhaber, Alberto M. LaRosa, Nagalingeswaran Kumarasamy, Adriana Andrade, Gautam Baheti, Courtney V. Fletcher, Thomas B. Campbell, David W. Haas, Samantha MaWhinney, Peter L. Anderson
J Antimicrob Chemother. 2016 Jun; 71(6): 1609–1618. Published online 2016 Feb 17. doi: 10.1093/jac/dkw005


Article   |   PubReader   |   PDF–343K   |   Cite

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV

Michael Li, Walter W. Chan, Stephen D. Zucker
J Am Heart Assoc. 2020 Oct 6; 9(19): e016310. Published online 2020 Sep 15. doi: 10.1161/JAHA.120.016310


Article   |   PubReader   |   PDF–543K   |   Cite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing

RS Gammal, MH Court, CE Haidar, OF Iwuchukwu, AH Gaur, M Alvarellos, C Guillemette, JL Lennox, M Whirl‐Carrillo, SS Brummel, MJ Ratain, TE Klein, BR Schackman, KE Caudle, DW Haas
Clin Pharmacol Ther. 2016 Apr; 99(4): 363–369. Published online 2015 Nov 9. doi: 10.1002/cpt.269


Article   |   PubReader   |   PDF–224K   |   Cite

Role of P-Glycoprotein in the Distribution of the HIV Protease Inhibitor Atazanavir in the Brain and Male Genital Tract

Kevin R. Robillard, Gary N. Y. Chan, Guijin Zhang, Charles la Porte, William Cameron, Reina Bendayan
Antimicrob Agents Chemother. 2014 Mar; 58(3): 1713–1722. doi: 10.1128/AAC.02031-13


Article   |   PubReader   |   PDF–865K   |   Cite

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation

Paul Leger, Sanika Chirwa, Jacinta N. Nwogu, Megan Turner, Danielle M. Richardson, Paxton Baker, Michael Leonard, Husamettin Erdem, Lana Olson, David W. Haas
Pharmacogenet Genomics. 2018 Jan; 28(1): 1–6. Published online 2017 Dec 13. doi: 10.1097/FPC.0000000000000316


Article   |   PubReader   |   PDF–255K   |   Cite

Association between bilirubin, atazanavir, and cardiovascular disease events among people living with HIV across the US.

Heidi M Crane, Robin M Nance, Susan R Heckbert, Corey Ritchings, Lisa Rosenblatt, Matthew Budoff, Brian R. Wood, David L. Tirschwell, H Nina Kim, William C Mathews, Elvin Geng, Richard D Moore, Peter W Hunt, Joseph J Eron, Greer A Burkholder, Daniel R Drozd, Felicia C. Chow, Kyra J. Becker, Joseph R. Zunt, Emily L. Ho, Rizwan Kalani, Andrew Huffer, Bridget M. Whitney, Michael S Saag, Mari M Kitahata, Joseph AC Delaney
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2019 Sep 15.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Aug 15; 81(5): e141–e147. doi: 10.1097/QAI.0000000000002071


Article   |   PubReader   |   PDF–89K   |   Cite

Drug and Drug Abuse Associated Hyperbilirubinemia: Experience with Atazanavir

Jayanta Roy-Chowdhury, Namita Roy-Chowdhury, Irving Listowsky, Allan W. Wolkoff
Clin Pharmacol Drug Dev. Author manuscript; available in PMC 2018 Mar 1.
Published in final edited form as: Clin Pharmacol Drug Dev. 2017 Mar; 6(2): 140–146. doi: 10.1002/cpdd.314


Article   |   PubReader   |   PDF–613K   |   Cite

Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s

Charles S Venuto, Jihoon Lim, Susan Messing, Peter W Hunt, Grace A McComsey, Gene D Morse
Antivir Ther. Author manuscript; available in PMC 2019 Jan 1.
Published in final edited form as: Antivir Ther. 2018; 23(4): 345–351. doi: 10.3851/IMP3209


Article   |   PubReader   |   PDF–327K   |   Cite

Genome-wide Association Study of Atazanavir Pharmacokinetics and Hyperbilirubinemia in AIDS Clinical Trials Group Protocol A5202

Daniel H. Johnson, Charles Venuto, Marylyn D. Ritchie, Gene D. Morse, Eric S. Daar, Paul J. McLaren, David W. Haas
Pharmacogenet Genomics. Author manuscript; available in PMC 2015 Apr 1.
Published in final edited form as: Pharmacogenet Genomics. 2014 Apr; 24(4): 195–203. doi: 10.1097/FPC.0000000000000034


Article   |   PubReader   |   PDF–234K   |   Cite

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir

Miriam Samuel, Daniel Bradshaw, Melissa Perry, Sum Yee Chan, Rageshri Dhairyawan, Laura Byrne, Katherine Smith, Judith Zhou, Charlotte Eve Short, Claire Naftalin, Ngozi Offodile, Sundhiya Mandalia, Sherie Roedling, Rimi Shah, Gary Brook, Mary Poulton, Mette Rodgers, Liat Sarner, Heather Noble, Philip Hay, Jane Anderson, Macky Natha, David Hawkins, Graham Taylor, Annemiek de Ruiter
Infect Dis Obstet Gynecol. 2014; 2014: 961375. Published online 2014 Sep 25. doi: 10.1155/2014/961375


Article   |   PubReader   |   PDF–521K   |   Cite

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir

Joshua A. Beckman, Brian R. Wood, Kevin L. Ard, Christin N. Price, Daniel A. Solomon, Jonah P. Zuflacht, Jessica Milian, Joshua C. Prenner, Paul E. Sax
PLoS One. 2017; 12(10): e0181993. Published online 2017 Oct 12. doi: 10.1371/journal.pone.0181993


Article   |   PubReader   |   PDF–1.2M   |   Cite

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals

Lauren E. Cain, Ellen C. Caniglia, Andrew Phillips, Ashley Olson, Roberto Muga, Santiago Pérez-Hoyos, Sophie Abgrall, Dominique Costagliola, Rafael Rubio, Inma Jarrín, Heiner Bucher, Jan Fehr, Ard van Sighem, Peter Reiss, François Dabis, Marie-Anne Vandenhende, Roger Logan, James Robins, Jonathan A. C. Sterne, Amy Justice, Janet Tate, Giota Touloumi, Vasilis Paparizos, Anna Esteve, Jordi Casabona, Rémonie Seng, Laurence Meyer, Sophie Jose, Caroline Sabin, Miguel A. Hernán
Medicine (Baltimore) 2016 Oct; 95(41): e5133. Published online 2016 Oct 14. doi: 10.1097/MD.0000000000005133


Article   |   PubReader   |   PDF–310K   |   Cite

Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients

Radojka M. Savic, Aurélie Barrail-Tran, Xavier Duval, George Nembot, Xavière Panhard, Diane Descamps, Céline Verstuyft, Bernard Vrijens, Anne-Marie Taburet, Cécile Goujard, France Mentré
Clin Pharmacol Ther. Author manuscript; available in PMC 2014 Mar 11.
Published in final edited form as: Clin Pharmacol Ther. 2012 Nov; 92(5): 575–583. Published online 2012 Oct 3. doi: 10.1038/clpt.2012.137


Article   |   PubReader   |   Cite

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study

Lisa Rosenblatt, Amanda M. Farr, Ella T. Nkhoma, James K. Nelson, Corey Ritchings, Stephen S. Johnston
BMC Infect Dis. 2016; 16: 492. Published online 2016 Sep 19. doi: 10.1186/s12879-016-1827-1


Article   |   PubReader   |   PDF–830K   |   Cite

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

Tony Antoniou, Leah Szadkowski, Sharon Walmsley, Curtis Cooper, Ann N. Burchell, Ahmed M. Bayoumi, Julio S. G. Montaner, Mona Loutfy, Marina B. Klein, Nima Machouf, Christos Tsoukas, Alexander Wong, Robert S. Hogg, Janet Raboud, The Canadian Observational Cohort (CANOC) collaboration
BMC Infect Dis. 2017; 17: 266. Published online 2017 Apr 11. doi: 10.1186/s12879-017-2379-8


Article   |   PubReader   |   PDF–583K   |   Cite

Boosted Lopinavir– Versus Boosted Atazanavir–Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries

The HIV-CAUSAL Collaboration
Clin Infect Dis. 2015 Apr 15; 60(8): 1262–1268. Published online 2015 Jan 6. doi: 10.1093/cid/ciu1167


Article   |   PubReader   |   PDF–154K   |   Cite

Atazanavir exposure in utero and neurodevelopment in infants: A comparative safety study

Ellen C. Caniglia, Kunjal Patel, Yanling Huo, Paige L. Williams, Suad Kapetanovic, Kenneth C. Rich, Patricia A. Sirois, Denise L. Jacobson, Sonia Hernandez-Diaz, Miguel A. Hernán, George R. Seage, III, for the Pediatric HIV/AIDS Cohort Study
AIDS. Author manuscript; available in PMC 2017 May 15.
Published in final edited form as: AIDS. 2016 May 15; 30(8): 1267–1278. doi: 10.1097/QAD.0000000000001052


Article   |   PubReader   |   PDF–457K   |   Cite

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function

Silvia A Guillemi, Sean H Ling, Julia S Dahlby, Benita Yip, Wendy Zhang, Mark W Hull, Viviane Dias Lima, Robert S Hogg, Ronald Werb, Julio S Montaner, Marianne Harris
J Int AIDS Soc. 2016; 19(1): 20995. Published online 2016 Sep 9. doi: 10.7448/IAS.19.1.20995


Article   |   PubReader   |   PDF–247K   |   Cite